Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
ALNYLAM PHARMACEUTICALS, INC. Chief Executive Officer Yvonne Greenstreet reported the vesting and conversion of 5,921 restricted stock units into an equal number of common shares on February 27, 2026. These RSUs were part of a 17,763-unit grant from February 27, 2023 that vests in three equal annual installments.
Following this derivative exercise, her directly held common stock increased to 91,583 shares. She also has 407 common shares held indirectly in a managed account. The transaction reflects equity compensation vesting, not an open-market purchase or sale.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported the vesting of restricted stock units that converted into common shares. On February 27, 2026, 1,908 restricted stock units were exercised at $0.00 and settled into 1,908 shares of common stock.
These RSUs were part of a 5,724‑unit grant awarded on February 27, 2023, which vested in three equal annual installments. The filing notes that this transaction represents the third and final tranche from that grant. Following the conversion, Poulton directly owned 61,710 shares of common stock, and an additional 57 shares were held indirectly through a managed account.
Alnylam Pharmaceuticals executive Tolga Tanguler acquired shares through equity compensation. On February 27, 2026, 1,666 restricted stock units were exercised at $0.00 per share and converted into 1,666 shares of common stock, increasing his directly held stake to 33,435 shares.
These RSUs were part of a 5,000-unit grant awarded on February 27, 2023 under the company’s Amended and Restated 2018 Stock Incentive Plan. The award vested in three equal annual installments, and this filing reflects the third and final tranche becoming fully vested and released.
ALNYLAM PHARMACEUTICALS, INC. executive vice president and Chief R&D officer Pushkal Garg reported both an equity award vesting and share sales. On February 27, 2026, 1,908 restricted stock units were converted into common shares at no cost as the final tranche of a February 27, 2023 grant vested. That same day, he sold a total of 4,627 shares of common stock in multiple open-market transactions at prices ranging from about $328.92 to $334.39 per share under a pre-established Rule 10b5-1 trading plan adopted on November 20, 2025. After these transactions, he directly held 22,129 common shares, with additional shares held indirectly in a managed account and in a trust where his spouse is co-trustee, and he disclaims beneficial ownership of the trust shares.
ALNYLAM PHARMACEUTICALS, INC. chief scientific officer Kevin Joseph Fitzgerald reported an equity award of company common stock. He acquired 158 shares of common stock on February 23, 2026 at a stated price of $0.00 per share as a grant/award.
According to the footnotes, this grant reflects shares issued in recognition of 20 years of continuous employment under a program that provides stock with an aggregate value of $100,000 to each qualifying employee, net of minimum statutory tax withholding. After this award, his directly held common stock totals 21,422 shares.
The filing also reports 537 shares of common stock held indirectly in a managed account, reflecting shares acquired through the company’s 401(k) matching contribution program.
Garg Pushkal reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 6,821 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 24,848 shares.
Greenstreet Yvonne reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 21,167 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 85,662 shares.
Tanguler Tolga reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 5,959 shares at a weighted average price of $310.08 per share. Following the reported transactions, holdings were 31,769 shares.
Fitzgerald Kevin Joseph reported multiple insider transaction types in a Form 4 filing for ALNY. The filing lists transactions totaling 8,000 shares at a weighted average price of $321.24 per share. Following the reported transactions, holdings were 21,264 shares.